Sector News

Germany's Merck explores sale of biosimilar drug business -sources

October 31, 2016
Life sciences

German chemicals and pharmaceuticals company Merck KGaA is exploring a sale of its biosimilars unit, according to people familiar with the matter, as that business faces fierce competition from larger players in the sector.

Biosimilars, the biotechnology-based equivalents of generic drugs, have become increasingly popular amid a drive to curb price increases. Stefan Oschmann, however, who took over as Merck’s CEO earlier this year, has been focused on finding ways to safeguard his company’s leading position in the multiple sclerosis market. Its top selling drug in this space is Rebif.

Merck has hired investment bank JPMorgan Chase & Co to sound out potential buyers for the biosimilar business, the people said on Friday. There is no guarantee that the discussions will result in any deal, they added.

Merck’s biosimilars business could be worth as much as $1 billion because of its long-term sales potential, the people said.

The sources asked not to be identified because the deliberations are confidential. Merck, which is independent of U.S. drug marker Merck & Co Inc, declined to comment. A JPMorgan spokeswoman offered no immediate comment.

Merck’s biosimilar business includes a drug in advanced clinical trials that is a competitor to AbbVie Inc’s popular arthritis treatment Humira. The unit also has several early-stage compounds.

Merck is facing off against several larger competitors, including Pfizer Inc and Novartis AG, both of which have won regulatory approval for biosimilar drugs.

Biosimilars have become an increasing area of focus for investors and industry executives in the past year, as regulators have begun approving a handful of compounds in the United States.

Biosimilars are more complex than traditional drugs, requiring genetically engineered proteins. The U.S. Food and Drug Administration was not allowed to consider generic versions of biologic drugs until U.S. President Barack Obama’s Affordable Care Act was enacted in 2010.

So far, the FDA has approved four biosimilar drugs, most recently a competitor for Humira made by Amgen Inc. There are more than 60 biosimilars awaiting approval.

More of those drugs are expected to be approved in the coming years, as biologic drugs representing more than $30 billion in sales will lose their patent protection between now and 2020, according to data from IMS Health.

In Europe, where biosimilars were approved by regulators as early as 2006, more than 21 biosimilars made by 14 companies have been approved.

By Carl O’Donnell and Greg Roumeliotis

Source: Reuters via Daily Mail

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).